2 Tower Pl, Suite 800
South San Francisco
Tel: (650) 825-6140
6 articles with Pionyr Immunotherapeutics
The collaboration with Pionyr Therapeutics demonstrates Lonza’s flexibility to tailor its offering to accommodate the specific needs of our customers. Our team has created a cell line development program relying on a state-of-the-art platform technology that brings a faster and streamlined approach to selecting an ideal cell line.
Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's antitumor immunity by altering the composition and function
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
PIONYR Immunotherapeutics, Inc. announced the appointment of Alicia Levey, Ph.D., as Senior Vice President and Chief Business Officer.
ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project
ProBioGen AG and Pionyr Immunotherapeutics, today announced a second service and license agreement to develop novel antibody therapeutics.
Pionyr was founded in 2015 by a UCSF professor and a Genentech alum.